Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin.

Many naturally occurring compounds, including beta-phenylethyl isothiocyanate (PEITC) and curcumin, exhibit significant anti-cancer chemopreventive effects. In this study, we investigated the combined effects of PEITC and curcumin in PC-3 human prostate cancer cells and in PC-3 cells that were stably transfected with an NF-kappaB luciferase plasmid (PC-3 C4). We found an additive effect of PEITC and curcumin for the induction of apoptosis. To elucidate the potential mechanisms of this effect, we studied several critical cellular signaling pathways, including the critical NF-kappaB cell survival signal that is hyper-activated in PC-3 cells and many other cancers. PEITC and curcumin additively inhibited NF-kappaB luciferase activity. Furthermore, the combined treatment significantly increased the activity of poly(ADP-Ribose) polymerase and cleavage of caspase-3 in correlation with apoptotic cell death. Studying upstream signaling events, we found that the phosphorylations of IkappaBalpha and Akt (Ser473, Thr308) were significantly attenuated by the combination of PEITC and curcumin. As these events can be downstream of the activation of epidermal growth factor receptor (EGFR), we pretreated PC-3 cells with PEITC and curcumin and then stimulated them with EGF. EGFR phosphorylations (Y845 and Y1068) were dramatically suppressed by PEITC or curcumin, and more so by the combination. Importantly, the degree of Akt and PI3K phosphorylations induced by EGF were also significantly suppressed. We conclude that the simultaneous targeting of EGFR, Akt and NF-kappaB signaling pathways by PEITC and curcumin could be the molecular targets by which PEITC and curcumin exert their additive inhibitory effects on cell proliferation and ultimately lead to programmed cell death of tumor cells.

[1]  A. Angelucci,et al.  Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro , 2005, International journal of cancer.

[2]  P. Karplus,et al.  A Novel Mechanism of Chemoprotection by Sulforaphane , 2004, Cancer Research.

[3]  A. Katz,et al.  Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. , 2000, Molecular urology.

[4]  R. Buttyan,et al.  Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo , 2001, The Prostate.

[5]  G. Bubley,et al.  Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. , 1999, The American journal of pathology.

[6]  R. Ratan,et al.  The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. , 2001, The Journal of biological chemistry.

[7]  C. Wood,et al.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. , 1998, British Journal of Cancer.

[8]  S. Rosenberg,et al.  implications for cancer therapy , 1996 .

[9]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[10]  Z. Zhai,et al.  NIK is a component of the EGF/heregulin receptor signaling complexes , 2003, Oncogene.

[11]  B. Aggarwal,et al.  Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines , 2001, Oncogene.

[12]  T. Ahmed,et al.  Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. , 2002, International journal of oncology.

[13]  R. Ratan,et al.  The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB , 2001, The Journal of Biological Chemistry.

[14]  A. Kong,et al.  Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase* , 2002, The Journal of Biological Chemistry.

[15]  A. Kong,et al.  Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells , 2005, Oncogene.

[16]  B. Hemmings,et al.  Inhibition of protein kinase B/Akt. implications for cancer therapy. , 2002, Pharmacology & therapeutics.

[17]  P. Harari,et al.  Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. , 2002, Molecular cancer therapeutics.

[18]  W. Zong,et al.  Mechanisms of constitutive NF‐κB activation in human prostate cancer cells , 2002, The Prostate.

[19]  Shivendra V. Singh,et al.  Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. , 2002, Cancer research.

[20]  Hong Zhang,et al.  Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis. , 2002, The Biochemical journal.

[21]  W. Kreis.  Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. , 1995, Cancer investigation.

[22]  C. Eaton,et al.  Growth Factor Receptors and Oncogene Expression in Prostate Cells , 1988, American journal of clinical oncology.

[23]  A. Whittemore,et al.  Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  Jayashree,et al.  Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. , 1990, Cancer research.

[25]  M. Maa,et al.  Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. , 2003, Biochemical pharmacology.

[26]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[27]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[28]  J. Dutcher,et al.  Therapeutic potential of curcumin in prostate cancer—IV: Interference with the osteomimetic properties of hormone refractory C4‐2B prostate cancer cells , 2004, The Prostate.

[29]  J. Stanford,et al.  Fruit and vegetable intakes and prostate cancer risk. , 2000, Journal of the National Cancer Institute.